Current Edition

The Benefits of Bacillus-derived Hyaluronic Acid

In Adding New and Improved Attributes to Existing Drug Formulations, and Offering Opportunities for New Delivery System Development
Jaypreet Dhillon, Editorial Manager at IPI, interviews Hans Ole Klingenberg at Novozymes Biopharma on the benefits and advances of the Bacillus-derived hyaluronic acid, and how this is adding new and improved attributes to the life-science industry, with progress in drug formulations and opportunities in new delivery system development. The interview highlights the potential of hyaluronic acid for drug delivery, and looks at concerns from the FDA, EMA and other regulatory bodies on its commercial availability; its advantages/ disadvantages; and how this technology is moving forward.